Chapter 15. Antiviral Agents against Respiratory Viruses

  1. Carlos Agustí2,3 and
  2. Antoni Torres2,3
  1. Michael G. Ison

Published Online: 7 JUL 2009

DOI: 10.1002/9780470714171.ch15

Pulmonary Infection in the Immunocompromised Patient: Strategies for Management

Pulmonary Infection in the Immunocompromised Patient: Strategies for Management

How to Cite

Ison, M. G. (2009) Antiviral Agents against Respiratory Viruses, in Pulmonary Infection in the Immunocompromised Patient: Strategies for Management (eds C. Agustí and A. Torres), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9780470714171.ch15

Editor Information

  1. 2

    Cap de Servei de Pneumologia i Allèrgia Respiratòria Hospital Clínic de Barcelona, Barcelona, Spain

  2. 3

    Institut Clinic de Pneumologia ICPCT, Hospital Clinic, C/Villarroel, 170, 08036 Barcelona, Spain

Author Information

  1. Northwestern University Feinberg School of Medicine, Divisions of Infectious Diseases & Organ Transplantation, Transplant & Immunocompromised Host Infectious Diseases Service, 676 N. Street Clair Street Suite 200, Chicago, IL 60611, USA

Publication History

  1. Published Online: 7 JUL 2009
  2. Published Print: 27 JAN 2009

ISBN Information

Print ISBN: 9780470319574

Online ISBN: 9780470714171

SEARCH

Keywords:

  • respiratory syncycial virus (RSV);
  • community respiratory viruses (CRVs);
  • antiviral agents against respiratory viruses;
  • neuraminidase inhibitors;
  • proprietary breath-activated device (DISKHALER);
  • Zanamivir and oseltamivir carboxylate resistance - mutations in viral haemagglutinin;
  • ribavirin in RSV infection treatment

Summary

This chapter contains sections titled:

  • M2 inhibitors

  • Neuraminidase inhibitors

  • Cidofovir

  • Ribavirin

  • Investigational agents

  • References